Expanding Footprint
With the opening of a new corporate headquarters in Seattle’s South Lake Union and expanded offices in South San Francisco and New York City, Adaptive continues to grow its employee base and increase the impact of its immune medicine platform in areas such as infectious diseases, autoimmune conditions, and cancer.
The Future of Immune Medicine
Adaptive is powering the age of immune medicine and propelling a paradigm shift in healthcare. The combination of our unique approach and the near-infinite applications of immune medicine provide opportunities to make a difference in the lives of people living with many different diseases, both now and in the future. This is just the beginning […]
Adaptive and Genentech Partner to Develop Personalized Cellular Therapies
Adaptive and Genentech join forces to develop shared and personalized T cell–based therapies for cancer patients, validating the therapeutic potential of Adaptive’s platform.
The First-Ever T Cell–Based Diagnostic Test
Adaptive launches T-Detect COVID, a novel diagnostic test for patients that uses the T cell as a marker to indicate recent or past infection. This is a small step for Adaptive and a large step towards Adaptive’s and Microsoft’s ultimate vision to develop T cell–based tests for early and accurate detection of many diseases from […]
clonoSEQ Expands to Third Indication for Chronic Lymphocytic Leukemia
For the first time, the FDA clears clonoSEQ for use as a blood-based test. Patients living with the most common type of leukemia have a new and convenient way to get answers about their disease and remission status.
Enabling a New Way to Measure Immunity
Adaptive launches immunoSEQ T-MAP COVID, a new tool for researchers that measures the T-cell response to vaccines in development and tracks the persistence of the responses over time.
Decoding the Immune Response to COVID-19
Adaptive, in partnership with Microsoft, points its platform against COVID-19. They share the data freely with researchers around the world to inform novel diagnostics, therapeutics, and vaccines via ImmuneCODE, the largest database ever developed of T-cell immune responses to this virus.
Adaptive is Born
Harlan and his brother, Chad Robins, found Adaptive TCR to meet the demand for this technology from academic institutions around the world.
500 Publications and Building
From narcolepsy to ovarian cancer. From HIV to SARS-CoV-2. From the healthy baseline of the immune repertoire to kidney transplantation. Adaptive continues to propel the understanding of the smallest details and the biggest insights of immune response.
Adaptive Goes Public
In one of the biggest biotech IPOs of the year, Harlan and Chad Robins ring the Nasdaq opening bell as Adaptive is listed under the ticker symbol ADPT.